Tolga Vural

How can organizations close the gap between current value & access capabilities and the competencies needed to succeed in today’s dynamic #medtech landscape? BCG's report offers a clear pathway for identifying crucial skills, customizing strategies for unique business environments, and applying practical steps to enhance team performance. Learn more here: https://on.bcg.com/3xfdhyh

5

FTI Consulting's Jason Shafrin, was recently featured in The Evidence Base® discussing the newly published paper, “Valuing the Societal Impact of Medicines and Other Health Technologies.” This user guide introduces generalized cost-effectiveness analysis (GCEA), a groundbreaking framework designed to provide a more inclusive approach to drug valuation and health policy decision-making. In this interview, Jason uncovers: • Why GCEA is a game-changer for healthcare decision-making • How GCEA addresses the limitations of traditional cost-effectiveness analysis (CEA) • The potential impact on healthcare policy and access to medicines Read the full interview below. *This article requires a log in, free account can be created to access the full article #Healthcare #HealthcareAccess #HealthcareInnovation #DrugValuation #FTIConsulting

1

🏥 From fueling clinical innovation to training the next generation of clinicians— academic medical centers (AMCs) play a critical role in US healthcare. Yet, despite significant growth, the financial performance of many AMCs has declined in recent years. In this new article, my McKinsey colleagues surveyed 100 AMC leaders to better understand the implications of their fiscal challenges and learn more about their responses to mounting pressure to improve performance. They outline several areas of focus that could help AMCs improve operational efficiency and enable reinvestments in their missions here ➡️ https://lnkd.in/efrXVfqh #financialsustainability #AMCs #fiscalhealth #hospitalcare

41

3 Comments

BCG and Massachusetts High Technology Council–in collaboration with leaders from industry, hospitals, and academia–examine AI’s transformative potential in patient care and life sciences in a recent white paper. Read to learn how we plan to lead in applied #AI, focusing on better patient outcomes and groundbreaking innovations: https://on.bcg.com/3xqah2s

18

1 Comment

The genomics industry is at a critical juncture. As sequencing costs fall and multi-omics gain traction, NGS clinical testing labs and life science equipment firms face a fast shifting marketplace. My BCG colleagues recent analysis investigates two possible outcomes: market contraction caused by cost erosion or expansion driven by content distinction. Learn more about the changing competitive dynamics and how to manage this new era of genomics: https://on.bcg.com/3zoUaCQ

11

Our recent white paper highlights findings on the significant disparities in treatment outcomes for Heart Failure with Reduced Ejection Fraction (HFrEF). Our study reveals critical gaps, particularly in underserved urban areas, calling for urgent and strategic interventions. Key Actions for #Healthcare Leaders: Engage with Data: Use your data effectively to understand and address these disparities. Promote Awareness: Communicate our findings to foster industry-wide enhancements. Implement Quick Wins: Focus on feasible improvements that can have an immediate impact.

2

Join us at #BIO2024 for a compelling session that delves into the heart of biopharma deals: "Is Oncology Still a Hot Spot for Biopharma Deals?" 📅 Date: Thursday, June 6, 2024 🕥 Time: 10:15 – 11:15 a.m. Oncology has long been the frontrunner in biopharma investments, with a staggering 37% of the clinical-stage drug pipeline dedicated to cancer treatments. But when it comes to M&A, the landscape is shifting. What does this mean for the industry? Our session will analyze industry data to compare oncology vs. non-oncology companies in the context of M&A and Alliances and gain our experts' opinions on where things are headed. Ben Hickey, Ross Aarons, Camille Landis, Christopher Mortko

70

3 Comments

BCG Roundtable Focused on Key Trends Shaping the Future of Clinical Operations   Was thrilled to host an energetic discussion at our inaugural Clinical Operations roundtable earlier this week with industry executives across biopharma to discuss the most pressing topics shaping these teams. Thank you to our BCG team that enabled this discussion John Wu, Najaf A. Shah Shah, Paul Hastwell, Deming Qin Rachel Magid Beatriz Monedero Álvarez. Four Key Trends from the Roundtable: 1. Simplifying Protocols to Improve Patient-Centricity and Equity Growing emphasis on reducing patient burden during clinical trials is reshaping clinical operations and clinical trial decision-making more broadly. Companies are leveraging data and analytics to design smarter, more inclusive trials while simplifying protocols for patients and sites. They are also bringing in patients to shape their protocols 2. Continuing to Accelerate Trial Timelines Site Activation and patient enrolment remain critical bottlenecks and a key discussion point, with participants sharing the strategies and initiatives they are pursuing (e.g., trial footprint and site mix adjustments, digital recruitment approaches and evolving site facing roles) to deliver trials faster. 3. Evolving Sourcing Models: To boost efficiency and capacity, companies are rethinking resource allocation, exploring more offshoring and functional service provider (FSP) to manage capacity; Full-service outsourcing (FSO) models still have a role, particularly for mid-sized companies and select studies 4. Harnessing (Gen)AI: GenAI is revolutionizing trial operations, from AI-powered design tools, automated document generation and dashboards to decentralized research and patient engagement. These innovations are set to enhance trial delivery and patient experience. Exciting times for Clinical Operations teams as they play a critical role in bringing medicines to patients faster in a cost-effective and efficient manner, with greater consideration of the patient experience and needs. To join us in future discussions, please get in touch at [email protected] #clinical, #trials, #GenAI

79

5 Comments

Color Health and OpenAI Collaborate to Transform Cancer Screening and Access to Expertise GenAI represents the biggest opportunity to enhance access to critical health information and services. Given the complexity and breadth of healthcare, a constant challenge is accessing expertise at crucial moments in a patient’s journey. Color Health and OpenAI have chosen to focus deeply on scaling the ability of clinicians to support a few specific, but highly impactful use cases constrained usually by access to specific experts. Their approach is unique in 3 several ways: 1/. Rather than going broad, they are focusing narrowly and deeply on a couple of specific use cases. This 'depth over breadth' strategy could be highly impactful. 2/. Cancer expertise is often scarce and absent when required along the patent journey. This solution aims to bring an oncologist's expertise into primary care interactions. 3/. The "copilot" product design approach should ensure that doctors do not experience the tool as a new piece of software, but rather as something that seamlessly integrates into their current workflow. Overall, this is a significant step in the right direction and supports our ability to 'do more with less'. I will be following this collaboration closely. The implications are immense for a range of areas beyond Cancer. #healthcare #artificialintelligence #AI #GenAI #Cancer #NHS https://lnkd.in/e-wzzeM4

10

Key actions for health industries dealmakers. Forward thinking. Staying several steps ahead to identify actions to drive growth, unlock value and create sustained outcomes. Transforming business models will continue to fuel M&A at a steady pace through the rest of 2024. #healthcare #healthindustry #healthstarcommercial

2

📢NEW: The Umbrex 2024 Report on Top Healthcare Consulting Firms covers 20 global firms with a strong healthcare practice and 28 specialty consulting firms focused on the healthcare industry. Please let me know if you'd like access at no charge 👇 For each firm, the report covers: ✅ Distinctive capabilities ✅ Notable thought leadership ✅ Differentiated aspects ✅ LinkedIn company page ✅ Website We created this report to serve as a resource for: + Industry execs seeking to identify the right firm to support their project needs + Individuals seeking a role at a top healthcare consulting firm ✍️ Let me know in the comments if you'd like access ➕ Join 71,000 who follow me, Will Bachman, for free consulting resources ♻️ Repost if your connections may find this valuable 📞 If you're looking for an independent consultant, Umbrex can find you the right person within 48 hours. Let's chat.

34

20 Comments

Have you been following the ‘Biopharma R&D Leadership Agenda’ series? We've reached the final installment, and it's a critical read for biopharma leaders aiming to drive transformational change within their organizations. The latest article, "Empowered Workforce," delves into the complexities of modern operating models and processes that often hinder efficiency and disempower teams. It highlights how BCG-supported process and governance redesigns have significantly simplified operations, enhanced responsiveness, and enabled teams to achieve outstanding results. Read the article here: https://lnkd.in/dqwz3VGn Let me know your thoughts in the comments below.

9

ZS’s 2024 #FutureofHealth Report explored some of the reasons why consumers aren’t more engaged with their healthcare. A recent study in U.S. News & World Report makes some interesting points about patient engagement and relationships. Many patients really like their provider, but to build a relationship, they need to be able to access care in the first place. https://lnkd.in/eXxj-ksh

4

Healthcare M&A activity remained strong in Q3 2024, driven by strategic acquisitions aimed at expanding service offerings and boosting operational efficiencies. As healthcare organizations continue to consolidate, the focus is on integrating technology, enhancing patient care, and complying with a changing regulatory environment. These mergers are not only reshaping the industry but also opening doors for innovation and collaboration in healthcare delivery. #HealthcareMergers #IndustryGrowth #HealthcareInnovation #EvergreenForFounders

1

What will it take to boost productivity in the biopharmaceutical industry, which has slumped for a decade or more? 📉 In this new article, my McKinsey colleagues Brandon Parry, Rachel Moss, Kate Smeitana, Michelle Suhendra spoke with hundreds of biopharma R&D leaders and drew on their own experience to help create a recipe for sustainable, value-creating innovation— even in the face of strengthening industry headwinds— to help make more medicines that matter to patients. Check it out here: https://lnkd.in/e_YutwMq #medicine #pharmaceuticals #research

19

Bain's latest quarterly survey reveals four key themes that highlight how executives' views on the technology have evolved in recent months. Explore the detailed results of our survey here. https://bit.ly/46GkeWl

1

FTI Consulting's Shanshan Wang and Jason Shafrin, along with Kirk W. Kerr and Philipp Schuetz, published an article diving into the health economic value of postdischarge oral nutrition supplement (ONS) consumption among elderly adults who were malnourished during hospitalization. By comparing the use of ONS to standard of care, our experts highlight the transformative potential of ONS in improving patient outcomes and reducing healthcare burdens. Read the full analysis below. #Healthcare #HealthOutcomes #Malnutrition #HealthcareInnovation #ONS #FTIConsulting #HealthEconomics #RealWorldEvidence

1

IT-BPS service providers are increasingly turning their attention to the mid-market, recognizing the untapped potential. To seize this opportunity, understanding what mid-market life sciences enterprises need from their service partners is the first step. #midmarket #IT #BPS

10

1 Comment

Joe Zaccaria and Lindsey Manning from KPMG US delve into how real-world data (RWD) is revolutionizing healthcare and life sciences. By embracing Generative AI and adhering to the latest FDA guidelines, early adopters are not only accelerating clinical development but also paving the way for value-based healthcare delivery. This strategic integration of RWD is enhancing patient outcomes and fostering significant industry partnerships. #RealWorldData #KPMGLifeSciences #HealthcareInnovation https://bit.ly/46qPtoj

1